Crescent Biopharma launches underwritten public offering of ordinary shares, pre-funded warrants

• Crescent Biopharma launched an underwritten public offering of ordinary shares or pre-funded warrants to buy ordinary shares.
• Underwriters hold a 30-day option to purchase up to 15% more ordinary shares at the offering price, less discounts.
• Jefferies, TD Cowen, Guggenheim Securities, Cantor lead the deal; LifeSci Capital acts as passive book-runner.
• Shares, pre-funded warrants sold by the company under an effective Form S-3 shelf registration statement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crescent Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-048347), on July 15, 2026, and is solely responsible for the information contained therein.